Connors James J II
Form 4
November 14, 2005

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Connors James J II

(Last) (First) (Middle)

C/O KELSO & COMPANY, 320 PARK AVENUE

(Street)

NEW YORK, NY 10022

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading Symbol
ENDO PHARMACEUTICALS HOLDINGS INC [ENDP]

3. Date of Earliest Transaction (Month/Day/Year)
11/07/2005

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

_____ Director
__X__ 10% Owner
_____ Officer (give title below)
_____ Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock, par value $.01 per share (1)	11/07/2005		X		1,315	D	$ 2.42	17,894,146	I	By Endo Pharma LLC (2) (3)
Common Stock, par value $.01 per share (1)	11/07/2005		X		1,146	D	$ 2.42	17,893,001	I	By Endo Pharma LLC (2) (3)
Common Stock, par value $.01	11/07/2005		X		3,946	D	$ 2.42	17,889,055	I	By Endo Pharma LLC (2) (3)

per share (1)								
Common Stock, par value $.01 per share (1)	11/07/2005	X	2,812	D	$ 2.42	17,886,243	I	By Endo Pharma LLC (2) (3)
Common Stock, par value $.01 per share (1)	11/07/2005	X	2,712	D	$ 2.42	17,883,532	I	By Endo Pharma LLC (2) (3)
Common Stock, par value $.01 per share (1)	11/07/2005	X	1,065	D	$ 2.42	17,882,466	I	By Endo Pharma LLC (2) (3)
Common Stock, par value $.01 per share (1)	11/07/2005	X	2,925	D	$ 3	17,879,541	I	By Endo Pharma LLC (2) (3)
Common Stock, par value $.01 per share (1)	11/07/2005	X	6,379	D	$ 3	17,873,162	I	By Endo Pharma LLC (2) (3)
Common Stock, par value $.01 per share (1)	11/07/2005	X	5,866	D	$ 3	17,867,296	I	By Endo Pharma LLC (2) (3)
Common Stock, par value $.01 per share (1)	11/07/2005	X	230	D	$ 3.42	17,867,066	I	By Endo Pharma LLC (2) (3)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(*e.g.*, puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)

			Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Call Option (obligation to sell)	$ 2.42	11/07/2005	X			1,315	10/13/2005	08/26/2007	Common Stock	1,315
Call Option (obligation to sell)	$ 2.42	11/07/2005	X			1,146	10/13/2005	08/26/2007	Common Stock	1,146
Call Option (obligation to sell)	$ 2.42	11/07/2005	X			3,946	10/13/2005	08/26/2007	Common Stock	3,946
Call Option (obligation to sell)	$ 2.42	11/07/2005	X			2,812	10/13/2005	08/26/2007	Common Stock	2,812
Call Option (obligation to sell)	$ 2.42	11/07/2005	X			2,712	10/13/2005	08/26/2007	Common Stock	2,712
Call Option (obligation to sell)	$ 2.42	11/07/2005	X			1,065	10/13/2005	08/26/2007	Common Stock	1,065
Call Option (obligation to sell)	$ 3	11/07/2005	X			2,925	10/13/2005	08/26/2007	Common Stock	2,925
Call Option (obligation to sell)	$ 3	11/07/2005	X			6,379	10/13/2005	08/26/2007	Common Stock	6,379
Call Option (obligation to sell)	$ 3	11/07/2005	X			5,866	10/13/2005	08/26/2007	Common Stock	5,866
Call Option (obligation to sell)	$ 3.42	11/07/2005	X			230	10/13/2005	08/26/2007	Common Stock	230

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Connors James J II C/O KELSO & COMPANY 320 PARK AVENUE NEW YORK, NY 10022		X		

Signatures

James J. Connors II	11/11/2005
**Signature of Reporting Person	Date

Explanation of Responses:

***** If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

****** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Kelso Investment Associates V, L.P. (KIA V") is the designated filer.

(2) KIA V may be deemed to share beneficial ownership of shares of Common Stock owned of record by Endo Pharma LLC by virtue of its status as a member of Endo Pharma LLC. KIA V shares investment and voting power along with the other members of Endo Pharma LLC with respect to secutieties owned by Endo Pharma LLC, but disclaims beneficial ownership of such securities except to the extent of its pecuniary interest.

(3) Each individual reporting person may be deemed to share beneficial ownership of shares of Common Stock owned of record by KIA V, by virtue of his status as a general partner of the general partner of KIA V, and each individual shares investment and voting power along with the other general partners of KIA V, but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.